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accordance with the current recommendations 
of the European Society of Cardiology.3 For as‑
ymptomatic patients, we maintained a proac‑
tive approach towards PVR. In all patients, we 
performed cardiac magnetic resonance imag‑
ing (MRI) as part of preoperative evaluation 
(FIGURE 1A). The RV end ‑diastolic volume (EDV) of 
163 ml/m² and RV end ‑systolic volume (ESV) of 
80 ml/m² were used to guide the decisions re‑
garding PVR in asymptomatic patients.4 Ethics 
committee approval was not required in this 
retrospective study.
Operative technique All patients underwent 
classic redo sternotomy and were operated us‑
ing a cardiopulmonary bypass at moderate hypo‑
thermia (esophageal temperature, 32°C), using 
a nonpulsatile roller pump with the blood flow 
of 2 to 2.4 l/min/m² and mean arterial pressure 
of 40 to 60 mm Hg. For maximum safety, arteri‑
al line was placed in the femoral artery prior to 
thoracotomy. RV remodeling was performed and 
a homologous pericardial patch (mean dimen‑
sions, 8.1 × 5.2 cm) was used. The Sorin Crown 
(Livanova, London, England) bioprosthetic valve 
for PVR was used in all cases.
Statistical analysis A 2‑tailed P value of less 
than 0.05 was considered significant. Contin‑
uous variables were presented as median (in‑
terquartile range [IQR]) due to the sample size. 
The Wilcoxon nonparametric test for paired sam‑
ples was used for comparison of continuous vari‑
ables, as appropriate.
Introduction Tetralogy of Fallot (ToF) is 
the most common cyanotic congenital heart 
disease.1 Symptoms are present at birth and 
may vary from mild to severe. Significant sur‑
vival improvement is observed following sur‑
gical ToF correction, which leads to late com‑
plications in survivors, such as progressive ex‑
ercise intolerance, arrhythmias, heart failure, 
and sudden cardiac death.2 A reoperation may 
be necessary in individuals with right ventric‑
ular (RV) failure due to pulmonary valve dys‑
function. Pulmonary valve replacement (PVR) 
is the treatment of choice in this clinical set‑
ting; however, data to support the choice of 
prosthesis are sparse.2 Good outcomes were 
reported with the use of bioprosthetic valves, 
but the clinical observations are limited. This 
prompted us to present the first Polish expe‑
rience with ToF reoperations comprising PVR 
with a bioprosthesis.
Methods A total of 27 consecutive patients 
with a history of ToF repair in childhood were 
referred for reoperation in the Department of 
Cardiovascular Surgery and Transplantology, 
Institute of Cardiology, Jagiellonian Universi‑
ty College of Medicine, John Paul II Hospital, 
Kraków, Poland, between 2012 and 2018. Four 
patients were previously reoperated, but none 
of them had PVR. Patients were included if in‑
dications for reoperation were satisfied (symp‑
tomatic deterioration and / or progressive RV 
dysfunction), as assessed by the local Grown‑
‑up Congenital Heart Disease Heart Team, in 
Correspondence to: 
Grzegorz Wasilewski, MD, PhD, 
Institute of Cardiology, 











S H O R T  C O M M U N I C A T I O N
Outcomes of tetralogy of Fallot reoperation 
in adults: a single ‑center experience with 
bioprosthetic pulmonary valve replacement
Grzegorz Wasilewski¹, Bogdan Suder¹, Anna Kędziora¹, Radosław Litwinowicz¹, 
Piotr Mazur¹, Lidia Tomkiewicz-Pająk², Bogusław Kapelak¹
1  Department of Cardiovascular Surgery and Transplantology, Institute of Cardiology, Jagiellonian University Medical College, John Paul II Hospital, Kraków, Poland
2  Department of Cardiovascular Diseases, Institute of Cardiology, Jagiellonian University Medical College, John Paul II Hospital, Kraków, Poland
S H O R T  C O M M U N I C A T I O N  ToF reoperation with a bioprosthetic pulmonary valve 923































































































 FIGURE 1 A – preoperative cardiac magnetic resonance imaging, transverse plane; B – indications for tetralogy of Fallot (ToF) 
reoperation; C – right ventricular (RV) echocardiographic parameters before and after ToF reoperation 
 Abbreviations: ASD, atrial septal defect; PVR, pulmonary valve replacement; RVSP, right ventricular systolic pressure; 
VSD, ventricular septal defect
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(IQR) postoperative peak gradient through pul‑
monary valve tended to be lower than preopera‑
tively (16 [9–21] mm Hg vs 20 [12–30] mm Hg; P 
= 0.056). The median (IQR) gradient also tended 
to be lower (9 [5–14] mm Hg vs 10 [6–17] mm Hg; 
P = 0.075). The outcomes are presented in FIGURE 1C.
The bioprosthetic aortic valve used in pulmo‑
nary position proved to be a good option. Sur‑
gical RV reduction with RVOT remodeling and 
pulmonary arterioplasty using the homologous 
pericardial patch provide excellent conditions 
for RV remodeling. In our study, we used only 
the Sorin Crown bioprosthetic aortic valve and 
the postoperative peak and mean transpulmo‑
nary gradients were satisfactory.
The optimal timing of PVR, especially in as‑
ymptomatic patients, is not clearly defined. 
The are no universal definitions of severe RV 
dilation and moderate ‑to ‑severe RV dysfunc‑
tion, and there are no prespecified criteria for 
qualifications.5 Several studies using MRI have 
addressed this issue by reporting cutoff values 
of preoperative RV ESV and EDV for successful 
RV remodeling after PVR.6 According to these 
studies, the cutoff RV EDV and ESV are about 
160 and 80 ml/m2, respectively. Those parame‑
ters reached similar values in our study. Tissue 
Doppler echocardiography may show diastolic 
abnormalities of RV and intraventricular sep‑
tum and should be considered during preoper‑
ative examination.7
The operative risk in our study was acceptable 
and there was one perioperative death. The re‑
ported acute kidney injury was transient and 
the renal replacement therapy was not needed. 
Subjective improvement of functional status 
is evident and persistent in our patients. Oth‑
er techniques of restoring the RVOT were also 
analyzed and proven to be effective, but if a val‑
vular intervention is required, a bioprosthesis 
is favored and is superior to a mechanical valve.
Study limitations This study has all limitations 
of a single ‑center retrospective observational 
study. Sample size is limited, yet this is the larg‑
est Polish cohort reported to date.
In conclusion, reoperation in young adult pa‑
tients after classic ToF repair in childhood with 
PVR using a bioprosthetic Sorin Crown valve 
has proven to be safe with good early‑ and long‑
‑term outcomes.
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Results and discussion A total of 27 patients 
with the median (IQR) age of 29 (23–35) years 
were analyzed. The sex distribution was almost 
equal (male sex, 14 [52%]). The median (IQR) age 
at the initial intracardiac repair was 5 (2–9.5) 
years; the correction was carried out in adulthood 
in 2 patients (8%). The median (IQR) time inter‑
val between the initial repair and reoperation was 
23 (19–27) years. The distribution of functional 
New York Heart Association was as follows: I (n = 
10 [37%]), II (n = 11 [40%]), III (n = 4 [15%]), and 
IV (n = 2 [8%]). The median (IQR) RV EDV and 
ESV in MRI was 151 (138–169) ml/m² and 71 (64–
92) ml/m², respectively. Indications for ToF re‑
operation in our cohort are presented in FIGURE 1B.
Surgery Aortic cross ‑clamp time depended 
on the need for concomitant procedures (me‑
dian [IQR], 81 [74–94.5] minutes). The median 
size of the Sorin Crown bioprosthetic valve in 
the pulmonary position was 25 mm. In all cas‑
es, surgical RV reduction with RV outflow tract 
(RVOT) and pulmonary trunk remodeling was 
performed, and in 5 cases (18%), additionally 
stenotic pulmonary branches arterioplasty us‑
ing the homologous pericardial patch was car‑
ried out. An additional surgical procedure was 
required in 16 cases (59%): tricuspid valve repair 
with an annuloplasty ring (n = 13 [48%]), resid‑
ual ventricular septal defect closure (n = 2 [8%]), 
and atrial septal defect closure (n = 3 [11%]). 
The Carpentier ‑Edwards Physio Tricuspid ring 
(Edwards Lifesciences, Irvine, California, Unit‑
ed States) was used for tricuspid annuloplasty.
Postoperative period There were no intraoper‑
ative mortalities. One patient (3.7%) died 1 day 
after the surgery due to multiple organ dysfunc‑
tion syndrome. The median (IQR) stay at the in‑
tensive care unit was 1.5 (1–3) days and the medi‑
an (IQR) postoperative hospitalization time was 
8 (7–9) days. All 26 patients were discharged in 
the New York Heart Association functional class 
I (n = 22 [84%]) or II (n = 4 [16%]). After a me‑
dian follow ‑up of 4.1 years (range, 2–7.2 years), 
26 patients were alive (96.3%). The analysis of 
biochemical parameters showed that temporary 
acute kidney injury occurred in 5 cases (19%).
Follow ‑up echocardiography No patients were 
lost to follow ‑up. The median (IQR) left ventric‑
ular ejection fraction on follow ‑up echocardiog‑
raphy was lower than preoperatively (60% [59%–
65%] vs 66% [63.75%–71.25%]; P <0.01) but still 
left ventricular ejection fraction was preserved. 
The RV median (IQR) dimension was significant‑
ly lower than in the preoperative period (30 [25–
33] mm vs 35 [31–41] mm; P <0.01). The medi‑
an (IQR) right ventricular systolic pressure on 
echocardiography after PVR was significantly 
lower than preoperatively (30 [27–40] mm Hg 
vs 39 [33–40] mm Hg; P = 0.039). The median 
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